Subacute inflammatory demyelinating polyneuropathy is an acquired immune-mediated demyelinating peripheral neuropathy defined by progression to nadir over four to eight weeks, electrophysiologic demyelination, and absence of relapse on follow-up for definite SIDP. It bridges the clinical timing gap between Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
Ask a research question about Subacute Inflammatory Demyelinating Polyneuropathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Subacute Inflammatory Demyelinating Polyneuropathy
creation_date: '2026-05-04T19:32:38Z'
updated_date: '2026-05-04T19:32:38Z'
description: >-
Subacute inflammatory demyelinating polyneuropathy is an acquired
immune-mediated demyelinating peripheral neuropathy defined by progression to
nadir over four to eight weeks, electrophysiologic demyelination, and absence
of relapse on follow-up for definite SIDP. It bridges the clinical timing gap
between Guillain-Barre syndrome and chronic inflammatory demyelinating
polyradiculoneuropathy.
category: Autoimmune
disease_term:
preferred_term: subacute inflammatory demyelinating polyneuropathy
term:
id: MONDO:0016102
label: subacute inflammatory demyelinating polyneuropathy
parents:
- Acute disease
- Demyelinating polyneuropathy
pathophysiology:
- name: Immune-mediated peripheral nerve demyelination
description: >-
SIDP is characterized by subacute immune-mediated demyelination in multiple
peripheral nerves, causing slowed conduction, conduction block, weakness,
sensory loss, and reduced reflexes.
downstream:
- target: Sensorimotor polyneuropathy
description: Demyelination disrupts peripheral motor and sensory signaling.
locations:
- preferred_term: peripheral nerve
term:
id: UBERON:0001021
label: nerve
cell_types:
- preferred_term: myelinating Schwann cell
term:
id: CL:0000218
label: myelinating Schwann cell
biological_processes:
- preferred_term: myelination
modifier: ABNORMAL
term:
id: GO:0042552
label: myelination
- preferred_term: immune response
modifier: ABNORMAL
term:
id: GO:0006955
label: immune response
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
electrophysiologic evidence of demyelination in at least two nerves
explanation: This diagnostic criterion directly supports multifocal peripheral nerve demyelination.
- name: Subacute monophasic inflammatory neuropathy course
description: >-
The defining temporal mechanism is progression over four to eight weeks with
no relapse during adequate follow-up in definite SIDP.
downstream:
- target: Subacute neuromuscular disability
description: Progressive demyelination over weeks produces accumulating weakness and sensory dysfunction.
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
progressive motor and/or sensory dysfunction consistent with neuropathy in more than one limb with time to nadir between 4 and 8 weeks
explanation: This directly supports the defining subacute progression window.
- name: Blood-nerve barrier dysfunction with elevated CSF protein
description: >-
Elevated CSF protein is common in SIDP and supports blood-nerve or
blood-CSF barrier dysfunction in inflammatory demyelinating neuropathy.
downstream:
- target: Elevated cerebrospinal fluid protein
description: Barrier dysfunction allows protein elevation in CSF without a specific pathogen.
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Spinal fluid protein was high in 93% of cases.
explanation: This directly supports CSF protein elevation as common supportive evidence in SIDP.
- name: Immune cell infiltration and macrophage-mediated demyelination
description: >-
Nerve biopsy evidence of inflammatory cells supports immune-cell infiltration
as part of the acquired demyelinating neuropathy process; macrophage-mediated
myelin injury is a plausible effector mechanism in the CIDP-spectrum context.
downstream:
- target: Immune-mediated peripheral nerve demyelination
description: Inflammatory cell infiltration can drive peripheral nerve myelin injury.
cell_types:
- preferred_term: macrophage
term:
id: CL:0000235
label: macrophage
- preferred_term: T cell
term:
id: CL:0000084
label: T cell
biological_processes:
- preferred_term: leukocyte migration
modifier: ABNORMAL
term:
id: GO:0050900
label: leukocyte migration
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Supportive criteria included high spinal fluid protein level (>55 mg/dL) and inflammatory cells in the nerve biopsy.
explanation: This directly supports inflammatory cell involvement in SIDP nerve biopsy; macrophage/T-cell specification is inferred from immune-mediated demyelinating neuropathy biology.
- name: Cerebrospinal fluid interleukin-8 biomarker signal
description: >-
IL-8 is an emerging CSF biomarker in adjacent inflammatory demyelinating
neuropathies, but current evidence is not SIDP-specific.
downstream:
- target: Blood-nerve barrier dysfunction with elevated CSF protein
description: CSF inflammatory biomarkers may reflect neuroinflammatory barrier dysfunction.
biological_processes:
- preferred_term: inflammatory response
modifier: ABNORMAL
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:38077366
reference_title: "Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
IL8 in CSF is validated as a diagnostic biomarker in GBS and CIDP
explanation: This supports inflammatory CSF biomarker relevance in adjacent demyelinating neuropathies but is not SIDP-specific.
phenotypes:
- category: Neurological
name: Muscle weakness
description: Progressive motor dysfunction and weakness are common SIDP manifestations.
phenotype_term:
preferred_term: Muscle weakness
term:
id: HP:0001324
label: Muscle weakness
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The two most common neuropathy types were a symmetric motor-sensory neuropathy and a pure motor neuropathy.
explanation: Motor neuropathy directly supports weakness as a core clinical manifestation.
- category: Neurological
name: Peripheral neuropathy
description: SIDP presents as neuropathy affecting more than one limb.
phenotype_term:
preferred_term: Peripheral neuropathy
term:
id: HP:0009830
label: Peripheral neuropathy
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
progressive motor and/or sensory dysfunction consistent with neuropathy in more than one limb with time to nadir between 4 and 8 weeks
explanation: This directly supports peripheral neuropathy involving multiple limbs.
- category: Neurological
name: Reduced tendon reflexes
description: Reduced or absent tendon reflexes are compatible with demyelinating polyneuropathy.
phenotype_term:
preferred_term: Reduced tendon reflexes
term:
id: HP:0001315
label: Reduced tendon reflexes
environmental:
- name: Antecedent infection
description: >-
A preceding infection or similar immune trigger was reported in a substantial
minority of SIDP cases, but no single pathogen is established.
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
An antecedent infection was found in 38% of cases.
explanation: This directly supports antecedent infection as a reported trigger context.
diagnosis:
- name: Nerve conduction study
description: >-
SIDP diagnosis requires electrophysiologic evidence of demyelination in at
least two nerves, combined with the 4- to 8-week progression window and
exclusion of other etiologies.
diagnosis_term:
preferred_term: nerve conduction study
results: Demyelinating nerve conduction abnormalities in at least two nerves support SIDP.
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
electrophysiologic evidence of demyelination in at least two nerves
explanation: This is one of the mandatory diagnostic criteria proposed by the foundational cohort.
- name: Cerebrospinal fluid protein assessment
description: >-
Elevated CSF protein is supportive rather than defining evidence for SIDP.
diagnosis_term:
preferred_term: clinical laboratory test
results: CSF protein greater than 55 mg/dL supports inflammatory demyelinating neuropathy.
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Supportive criteria included high spinal fluid protein level (>55 mg/dL) and inflammatory cells in the nerve biopsy.
explanation: This directly supports CSF protein elevation as a supportive diagnostic criterion.
treatments:
- name: Corticosteroid therapy
description: >-
Prednisone was the main therapy in the foundational SIDP cohort, with high
rates of complete or partial recovery.
treatment_term:
preferred_term: corticosteroid therapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: corticosteroid
term:
id: CHEBI:50858
label: corticosteroid
target_phenotypes:
- preferred_term: Muscle weakness
term:
id: HP:0001324
label: Muscle weakness
evidence:
- reference: PMID:14663033
reference_title: Subacute inflammatory demyelinating polyneuropathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Almost all patients were treated with prednisone and some with additional immunotherapies. Complete recovery was achieved in 69% of cases and partial recovery in others.
explanation: This directly supports corticosteroid-centered treatment in the original SIDP cohort.
- name: Intravenous immunoglobulin therapy
description: >-
IVIg is used in CIDP-spectrum inflammatory demyelinating neuropathies and may
be considered when SIDP versus CIDP remains uncertain.
treatment_term:
preferred_term: intravenous immunoglobulin therapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: human immunoglobulin G
term:
id: NCIT:C80829
label: Human Immunoglobulin G
target_phenotypes:
- preferred_term: Peripheral neuropathy
term:
id: HP:0009830
label: Peripheral neuropathy
evidence:
- reference: PMID:34085743
reference_title: "European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
intravenous immunoglobulin (IVIg) or corticosteroids are strongly recommended as initial treatment in typical CIDP and CIDP variants
explanation: This guideline supports IVIg for adjacent CIDP-spectrum disease; SIDP-specific evidence is less direct.
- name: Plasma exchange
description: Plasma exchange is a rescue option in CIDP-spectrum inflammatory demyelinating neuropathy.
treatment_term:
preferred_term: plasma exchange
term:
id: NCIT:C15304
label: Plasmapheresis
evidence:
- reference: PMID:34085743
reference_title: "European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
plasma exchange is strongly recommended if IVIg and corticosteroids are ineffective
explanation: This guideline supports plasma exchange in CIDP-spectrum disease but is not SIDP-specific.
clinical_trials: []
datasets: []
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Subacute Inflammatory Demyelinating Polyneuropathy covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Subacute inflammatory demyelinating polyneuropathy (SIDP) is an acquired immune-mediated demyelinating peripheral neuropathy defined primarily by a subacute tempo (nadir 4–8 weeks) and (in “definite SIDP”) a monophasic, non-relapsing course on longitudinal follow-up. It sits in the clinical time-course “gray zone” between Guillain–Barré syndrome/acute inflammatory demyelinating polyradiculoneuropathy (GBS/AIDP; nadir ≤4 weeks) and chronic inflammatory demyelinating polyneuropathy (CIDP; progression >8 weeks or relapsing). SIDP is diagnosed using clinical features plus electrodiagnostic demyelination, supported by elevated CSF protein and (occasionally) nerve biopsy evidence of demyelination/inflammation. In the foundational SIDP cohort (Neurology 2003), immunotherapy—especially corticosteroids—was associated with high rates of recovery, but a subset initially labeled “probable SIDP” relapsed and was later reclassified as CIDP, underscoring the importance of follow-up. (oh2003subacuteinflammatorydemyelinating pages 1-2, oh2003subacuteinflammatorydemyelinating pages 3-4, bergh2021europeanacademyof pages 4-5)
| Feature | SIDP (4–8 weeks) evidence | GBS/AIDP comparator | CIDP/A-CIDP comparator | Notes/implications | Key citations |
|---|---|---|---|---|---|
| Core definition / time to nadir | Distinct subacute inflammatory demyelinating neuropathy with progression to nadir in 4–8 weeks; Oh et al. proposed definite/probable SIDP criteria. Mean progression in their cohort was ~1.6–1.7 months. | AIDP/GBS usually reaches nadir within ≤4 weeks and is typically monophasic. | Typical CIDP progresses >8 weeks; A-CIDP may begin acutely but later continues beyond 8 weeks or relapses repeatedly. | SIDP occupies the temporal “gray zone” between acute GBS and chronic CIDP. | (oh2003subacuteinflammatorydemyelinating pages 1-2, oh2003subacuteinflammatorydemyelinating pages 4-5, bergh2021europeanacademyof pages 4-5, lewis2017chronicinflammatorydemyelinating pages 1-4) |
| Course pattern | Definite SIDP is monophasic by definition and requires no relapse on adequate follow-up (Oh used ≥2 years). | GBS is also classically monophasic, though treatment-related fluctuations can occur. | CIDP is progressive or relapsing; A-CIDP may relapse or deteriorate after week 8 and/or have ≥3 relapses after initial improvement. | Longitudinal follow-up is essential; early cases may be reclassified. | (oh2003subacuteinflammatorydemyelinating pages 1-2, oh2003subacuteinflammatorydemyelinating pages 4-5, bergh2021europeanacademyof pages 4-5, alessandro2018differencesbetweenacute‐onset pages 1-8) |
| Relapse frequency | In Oh 2003, 17% of probable SIDP relapsed and were reclassified; 0% of definite SIDP relapsed. | Some GBS patients fluctuate after treatment, but persistent chronic evolution is not typical. | CIDP relapse rate in Oh cohort was 50%; guideline notes up to 13% of CIDP can present as acute-onset CIDP. | Relapse after the subacute window strongly favors CIDP/A-CIDP over true SIDP. | (oh2003subacuteinflammatorydemyelinating pages 3-4, bergh2021europeanacademyof pages 4-5, alessandro2018differencesbetweenacute‐onset pages 1-8) |
| Typical clinical phenotype | Often symmetric motor-sensory or pure motor neuropathy; cranial nerve and respiratory involvement were rare in Oh series. Antecedent infection occurred in 38%. | GBS more often has antecedent infection (>70% in review context) and may have more cranial/autonomic/respiratory involvement. | A-CIDP/CIDP more often has sensory signs/proprioceptive deficits and less cranial/respiratory/autonomic involvement than GBS; antecedent infection less common than SIDP in Oh cohort. | Clinical phenotype overlaps broadly; tempo plus follow-up is more discriminating than symptoms alone. | (oh2003subacuteinflammatorydemyelinating pages 1-2, oh2003subacuteinflammatorydemyelinating pages 3-4, bergh2021europeanacademyof pages 4-5, lewis2017chronicinflammatorydemyelinating pages 1-4) |
| Sensory ataxia / proprioception | Not a defining SIDP marker, but overlap with CIDP sensory features exists. | Less frequent in AIDP than A-CIDP in Alessandro et al. | In Alessandro 2018, A-CIDP had more proprioceptive disturbance (83% vs 28%) and sensory ataxia (46% vs 16%) than AIDP. | Prominent proprioceptive loss during an acute-subacute presentation should raise suspicion for CIDP-spectrum disease rather than pure GBS. | (alessandro2018differencesbetweenacute‐onset pages 1-8) |
| Electrophysiology | Demyelination required in ≥2 nerves for diagnosis; documented in nearly all SIDP cases, with latency prolongation and slowed motor NCV particularly helpful; conduction block/dispersion in ~50%. | AIDP is also demyelinating electrophysiologically, so early distinction from SIDP may be difficult. | CIDP diagnosis likewise depends on demyelinating NCS criteria; 2021 EAN/PNS refined motor and sensory criteria for typical and variant CIDP. | NCS is central but not fully disease-specific; serial studies may help if classification remains uncertain. | (oh2003subacuteinflammatorydemyelinating pages 1-2, oh2003subacuteinflammatorydemyelinating pages 3-4, doorn2024challengesinthe media a605ddf1) |
| CSF findings | CSF protein usually elevated; Oh reported 93% high protein in definite SIDP. | Albuminocytologic dissociation is common in GBS as well. | CSF protein elevation is also common in CIDP; supportive, not specific. | CSF supports inflammatory demyelinating neuropathy but does not cleanly separate SIDP from GBS/CIDP. | (oh2003subacuteinflammatorydemyelinating pages 1-2, oh2003subacuteinflammatorydemyelinating pages 2-3, stino2021chronicinflammatorydemyelinating pages 1-3) |
| Nerve biopsy / pathology | Supportive only; demyelination commonly seen, inflammatory cells in a minority, onion bulbs generally absent in SIDP series. | Biopsy is not routine for GBS. | Chronic CIDP may show more chronic changes such as onion bulbs/remyelination. | Biopsy can support an acquired inflammatory neuropathy when NCS are equivocal, but is not first-line. | (oh2003subacuteinflammatorydemyelinating pages 2-3, oh2003subacuteinflammatorydemyelinating pages 3-4, ramchandren2009chronicneuropathieschronicinflammatory pages 3-6) |
| Response to immunotherapy | Oh reported high treatment responsiveness, mainly to prednisone; complete recovery in 69% of definite SIDP. | GBS usually treated with IVIg or plasma exchange; corticosteroids are not standard effective therapy. | CIDP responds to IVIg, corticosteroids, and plasma exchange, but often needs maintenance therapy; A-CIDP often requires chronic immunotherapy. | Steroid responsiveness in a 4–8 week demyelinating neuropathy can point away from GBS and toward SIDP/CIDP spectrum. | (oh2003subacuteinflammatorydemyelinating pages 3-4, oh2003subacuteinflammatorydemyelinating pages 4-5, bergh2021europeanacademyof pages 4-5, doorn2024challengesinthe pages 1-2) |
| Recovery / prognosis | Better short- to medium-term outcome than CIDP in Oh study; overall high full-recovery rate. | GBS outcome varies widely; severe respiratory/autonomic disease can occur. | CIDP carries higher risk of chronic disability and treatment dependence if not recognized early. | SIDP may be a relatively favorable monophasic inflammatory demyelinating neuropathy if it does not relapse. | (oh2003subacuteinflammatorydemyelinating pages 3-4, doorn2024challengesinthe pages 1-2) |
| Early diagnostic pitfall | By definition, SIDP cannot be fully confirmed immediately because relapse exclusion needs follow-up; some cases first labeled GBS later prove SIDP or A-CIDP. | Onset <4 weeks is a red flag for GBS in CIDP workup. | 2024 review emphasizes mis/underdiagnosis in CIDP and need to reassess when phenotype, NCS, or treatment response are atypical. | In real-world practice, SIDP is often a working diagnosis pending longitudinal evolution. | (oh2003subacuteinflammatorydemyelinating pages 4-5, doorn2024challengesinthe pages 2-3, doorn2024challengesinthe pages 1-2, bergh2021europeanacademyof pages 4-5) |
| Biomarkers / recent research | Evidence remains limited specifically for SIDP; in a 2023 biomarker study, only 3 SIDP cases were included, and SIDP patients had higher CSF IL-8 than CIDP in a small exploratory comparison. | IL-8 is elevated in GBS and correlates with severity/outcome. | IL-8 is also elevated in CIDP vs healthy/non-inflammatory controls, but no validated SIDP-specific biomarker exists. | Recent biomarker work is promising for the broader inflammatory demyelinating neuropathy spectrum, but not yet SIDP-specific or practice-defining. | (kmezic2023validationofelevated pages 1-2, kmezic2023validationofelevated pages 3-4) |
Table: This table compares subacute inflammatory demyelinating polyneuropathy with GBS/AIDP and CIDP/A-CIDP using the most clinically useful differentiators: timing, relapse pattern, symptoms, electrophysiology, CSF, treatment response, and recent biomarker evidence.
Oh et al. (Neurology, 2003-12; DOI URL: https://doi.org/10.1212/01.wnl.0000096166.28131.4c) proposed SIDP as a distinct inflammatory demyelinating polyneuropathy with time to nadir between 4 and 8 weeks, and for “definite SIDP” a monophasic course with no relapse during “adequate follow-up” (≥2 years in the study). (oh2003subacuteinflammatorydemyelinating pages 1-2, oh2003subacuteinflammatorydemyelinating pages 4-5)
Within the tool-retrieved primary literature set used here, SIDP appears mainly as a clinical descriptive term and was not successfully mapped to a disease identifier in OpenTargets; I could not verify a MONDO/Orphanet/ICD/MeSH identifier from the retrieved evidence alone. (oh2003subacuteinflammatorydemyelinating pages 1-2)
Knowledge base note: For coding, SIDP is often represented in practice as part of the acquired immune-mediated demyelinating polyneuropathy spectrum (GBS/AIDP vs CIDP vs A-CIDP) rather than as a widely standardized standalone ontology entry in the sources retrieved here. (ramchandren2009chronicneuropathieschronicinflammatory pages 1-3, bergh2021europeanacademyof pages 4-5)
Evidence in this report is derived from: * Aggregated disease-level resources (CIDP guideline/review) (bergh2021europeanacademyof pages 4-5, doorn2024challengesinthe pages 1-2) * Primary cohort/series evidence for SIDP (Oh et al., 2003) (oh2003subacuteinflammatorydemyelinating pages 1-2) * Biomarker primary research in inflammatory neuropathies including a small number of SIDP cases (Kmezic et al., 2023) (kmezic2023validationofelevated pages 3-4)
SIDP is best supported as an acquired immune-mediated demyelinating neuropathy, within the broader CIDP/GBS spectrum. (oh2003subacuteinflammatorydemyelinating pages 1-2, dyck2018historydiagnosisand pages 2-3)
Antecedent infection: In the Oh et al. SIDP cohort, antecedent infection/events were reported in 38% of cases. (oh2003subacuteinflammatorydemyelinating pages 1-2)
Metabolic comorbidity as a differentiator in acute-onset CIDP (not SIDP-specific): In a retrospective comparison of AIDP vs acute-onset CIDP (A-CIDP), diabetes mellitus was more frequent in A-CIDP (29% vs 8%). (alessandro2018differencesbetweenacute‐onset pages 1-8)
No protective genetic or environmental factors were identified in the retrieved SIDP-specific evidence set. (oh2003subacuteinflammatorydemyelinating pages 2-3)
No SIDP-specific gene–environment interaction evidence was identified in the retrieved set.
Oh et al. reported that SIDP commonly presents as symmetric motor–sensory polyneuropathy or pure motor subtype; cranial nerve deficits and respiratory failure were rare. (oh2003subacuteinflammatorydemyelinating pages 1-2, oh2003subacuteinflammatorydemyelinating pages 2-3)
Tempo is defining: nadir 4–8 weeks. (oh2003subacuteinflammatorydemyelinating pages 1-2)
(These are ontology mappings for knowledge base use; not claims of prevalence.) * Areflexia — HP:0001284 * Muscle weakness — HP:0001324 * Distal muscle weakness — HP:0002460 * Sensory neuropathy — HP:0009830 * Hypoesthesia — HP:0001251 * Paresthesia — HP:0003401 * Gait ataxia / sensory ataxia (if prominent) — HP:0002066 * Elevated CSF protein — HP:0030208 (term naming may vary across releases)
SIDP-specific QoL instrument data were not identified in the retrieved SIDP cohort excerpt; however, CIDP-spectrum disease can cause disability affecting walking and activities of daily living. (stino2021chronicinflammatorydemyelinating pages 1-3)
No monogenic causal genes for SIDP were identified in the retrieved evidence set; SIDP is treated as acquired autoimmune. (oh2003subacuteinflammatorydemyelinating pages 2-3)
Not established for SIDP in the retrieved evidence set.
In Oh et al. (SIDP), a broad autoantibody panel (GM1, GQ1b, GD1a/1b, MAG, etc.) was largely negative; only one sensory definite SIDP case had positive IgG GM1/asialo-GM1/sulfatide antibodies. (oh2003subacuteinflammatorydemyelinating pages 2-3)
In CIDP-spectrum disease more broadly, autoantibodies to paranodal targets (eg, NF155) occur in a subset (reported ~4–18% in a high-citation review). (bunschoten2019progressindiagnosis pages 3-5)
The most consistently reported “environmental” antecedent in SIDP is preceding infection/illness (38% in the Neurology 2003 cohort). (oh2003subacuteinflammatorydemyelinating pages 1-2)
Other environmental/lifestyle risk factors were not established from the retrieved evidence set.
Specific pathogens were not identified in the retrieved SIDP cohort excerpt; the evidence is at the level of “antecedent infection” rather than a defined organism. (oh2003subacuteinflammatorydemyelinating pages 1-2)
The best-supported mechanistic model for SIDP uses CIDP-spectrum immunopathology as the closest framework: 1. Immune activation → autoreactive cellular and humoral immunity (T cells and antibodies) (mathey2015chronicinflammatorydemyelinating pages 3-4) 2. Blood–nerve barrier (BNB) dysfunction enabling immune cell trafficking and access of humoral factors to endoneurium (mathey2015chronicinflammatorydemyelinating pages 3-4) 3. Macrophage-mediated demyelination and segmental demyelination/remyelination causing conduction slowing/block and sensorimotor deficits (dyck2018historydiagnosisand pages 2-3, mathey2015chronicinflammatorydemyelinating pages 3-4) 4. In subgroups, autoantibodies to nodal/paranodal proteins and complement-mediated injury may contribute in CIDP-spectrum disease (bunschoten2019progressindiagnosis pages 3-5, mathey2015chronicinflammatorydemyelinating pages 3-4)
In the SIDP cohort, nerve biopsy criteria included demyelination/remyelination features and “mononuclear cell infiltration” in some cases; CSF protein elevation is consistent with barrier dysfunction. (oh2003subacuteinflammatorydemyelinating pages 2-3)
CIDP pathology is characterized by segmental demyelination/remyelination, onion-bulb formation, and mononuclear inflammatory infiltrates (often perivascular). (dyck2018historydiagnosisand pages 2-3)
(For knowledge base annotation; not disease-specific claims of enrichment.) * Myelination — GO:0042552 * Demyelination — GO:0032291 * Axon ensheathment — GO:0008366 * Leukocyte migration — GO:0050900 * Regulation of immune response — GO:0050776 * Complement activation — GO:0006956
Primary system: Peripheral nervous system (peripheral nerves, roots) consistent with inflammatory demyelinating polyneuropathy. (oh2003subacuteinflammatorydemyelinating pages 1-2)
SIDP is defined by subacute progression to maximal deficit (nadir) between 4 and 8 weeks. (oh2003subacuteinflammatorydemyelinating pages 1-2)
SIDP-specific population incidence/prevalence estimates were not identified in the retrieved SIDP-focused evidence.
Proxy epidemiology from CIDP reviews: * CIDP incidence reported as 0.5–3.3 per 100,000 (2024 review). (doorn2024challengesinthe pages 1-2) * CIDP prevalence estimates 0.8–1.9 per 100,000 (review context). (lewis2017chronicinflammatorydemyelinating pages 1-4)
Not applicable as a primary model; SIDP is acquired immune-mediated in the retrieved evidence. (oh2003subacuteinflammatorydemyelinating pages 2-3)
Oh et al. proposed criteria for definite SIDP including: (i) progressive motor/sensory dysfunction in >1 limb with time to nadir 4–8 weeks, (ii) electrophysiologic demyelination in ≥2 nerves, (iii) no other etiology, and (iv) no relapse on adequate follow-up (≥2 years). Supportive criteria included CSF protein ≥55 mg/dL and inflammatory cells on nerve biopsy. (oh2003subacuteinflammatorydemyelinating pages 1-2)
SIDP requires demyelinating features on NCS/EMG; in the Oh cohort, demyelination in ≥2 nerves was documented in 93% of probable and all definite cases; key helpful measures included distal latency prolongation and slowed motor conduction velocity, with conduction block/temporal dispersion in ~50%. (oh2003subacuteinflammatorydemyelinating pages 3-4, oh2003subacuteinflammatorydemyelinating pages 2-3)
In Oh et al., CSF protein >55 mg/dL was present in 89% (probable) and 93% (definite) SIDP; CSF protein range 35–800 mg/dL, mean 124 mg/dL; cell counts were generally low. (oh2003subacuteinflammatorydemyelinating pages 2-3)
In CIDP diagnostic workflows, supportive tests include imaging and biopsy; the 2024 review provides a diagnostic algorithm and practical red flags and supportive investigations. (doorn2024challengesinthe media 1489a645)
The 2024 CIDP review highlights that onset <4 weeks is a red flag suggestive of GBS rather than CIDP, and provides a structured approach to reduce misdiagnosis. (doorn2024challengesinthe pages 2-3, doorn2024challengesinthe media a605ddf1)
Oh et al. reported complete recovery in 69% of definite SIDP; overall improvement was high, with most recovery occurring within 2 years, motivating their ≥2-year follow-up requirement. (oh2003subacuteinflammatorydemyelinating pages 1-2, oh2003subacuteinflammatorydemyelinating pages 3-4)
Robust SIDP-specific prognostic markers were not identified in the retrieved set; however, distinguishing monophasic SIDP from evolving CIDP requires follow-up, and relapse strongly suggests CIDP-spectrum disease. (oh2003subacuteinflammatorydemyelinating pages 3-4)
In the Neurology 2003 cohort, prednisone (corticosteroids) was the main therapy, with IVIg and plasma exchange used in some; most treated patients improved, and complete recovery was frequent. A subset of “probable SIDP” relapsed and required longer-term maintenance immunotherapy (suggesting those cases were CIDP). (oh2003subacuteinflammatorydemyelinating pages 4-5, oh2003subacuteinflammatorydemyelinating pages 3-4)
The EAN/PNS 2021 guideline states principal recommendations including: initial treatment with IVIg or corticosteroids, and plasma exchange if ineffective, with maintenance treatment including IVIg/SCIg/corticosteroids. (bergh2021europeanacademyof pages 4-5)
The 2024 review provides a practical table of first-line treatment options, including dosage and side effects, and emphasizes objective monitoring and reassessment if response is poor. (doorn2024challengesinthe media b86e8bf0, doorn2024challengesinthe media 87bdfab1)
A 2023 Frontiers in Immunology study validated CSF IL-8 as a diagnostic biomarker for GBS and CIDP and prognostic in GBS; it included 3 SIDP cases in the cohort, highlighting how rare SIDP is in biomarker datasets and that SIDP-specific biomarker validation remains incomplete. The paper also explicitly notes IL-8 biology: “The main function of IL8 is the recruitment of neutrophils, but also T cells, and dendritic cells to the site of inflammation.” (2023-11-23; DOI URL: https://doi.org/10.3389/fimmu.2023.1241199). (kmezic2023validationofelevated pages 3-4, kmezic2023validationofelevated pages 2-3)
No established primary prevention is supported in the retrieved SIDP evidence. Practical prevention is primarily secondary/tertiary: early recognition of treatable immune-mediated neuropathy and timely initiation of effective therapy to reduce irreversible axonal damage, as emphasized for CIDP in 2024. (doorn2024challengesinthe pages 1-2)
No naturally occurring SIDP analog in non-human species was identified in the retrieved evidence set.
No SIDP-specific model organism was identified in the retrieved evidence set. Mechanistic insights in the broader immune-mediated neuropathy field often use experimental autoimmune neuritis models (GBS-like), but these were not SIDP-specific in the retrieved 2023–2024 evidence. (kmezic2025biomarkerandpathogenic pages 41-44)
References
(oh2003subacuteinflammatorydemyelinating pages 1-2): S. J. Oh, K. Kurokawa, D. F. de Almeida, H. F. Ryan, and G. C. Claussen. Subacute inflammatory demyelinating polyneuropathy. Neurology, 61:1507-1512, Dec 2003. URL: https://doi.org/10.1212/01.wnl.0000096166.28131.4c, doi:10.1212/01.wnl.0000096166.28131.4c. This article has 137 citations and is from a highest quality peer-reviewed journal.
(oh2003subacuteinflammatorydemyelinating pages 3-4): S. J. Oh, K. Kurokawa, D. F. de Almeida, H. F. Ryan, and G. C. Claussen. Subacute inflammatory demyelinating polyneuropathy. Neurology, 61:1507-1512, Dec 2003. URL: https://doi.org/10.1212/01.wnl.0000096166.28131.4c, doi:10.1212/01.wnl.0000096166.28131.4c. This article has 137 citations and is from a highest quality peer-reviewed journal.
(bergh2021europeanacademyof pages 4-5): Peter Y. K. Van den Bergh, Pieter A. van Doorn, Robert D. M. Hadden, Bert Avau, Patrik Vankrunkelsven, Jeffrey A. Allen, Shahram Attarian, Patricia H. Blomkwist‐Markens, David R. Cornblath, Filip Eftimov, H. Stephan Goedee, Thomas Harbo, Satoshi Kuwabara, Richard A. Lewis, Michael P. Lunn, Eduardo Nobile‐Orazio, Luis Querol, Yusuf A. Rajabally, Claudia Sommer, and Haluk A. Topaloglu. European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force—second revision. Journal of the Peripheral Nervous System, 26:242-268, Jul 2021. URL: https://doi.org/10.1111/jns.12455, doi:10.1111/jns.12455. This article has 1091 citations and is from a peer-reviewed journal.
(oh2003subacuteinflammatorydemyelinating pages 4-5): S. J. Oh, K. Kurokawa, D. F. de Almeida, H. F. Ryan, and G. C. Claussen. Subacute inflammatory demyelinating polyneuropathy. Neurology, 61:1507-1512, Dec 2003. URL: https://doi.org/10.1212/01.wnl.0000096166.28131.4c, doi:10.1212/01.wnl.0000096166.28131.4c. This article has 137 citations and is from a highest quality peer-reviewed journal.
(lewis2017chronicinflammatorydemyelinating pages 1-4): Richard A. Lewis. Chronic inflammatory demyelinating polyneuropathy. Current Opinion in Neurology, 30:508-512, Oct 2017. URL: https://doi.org/10.1097/wco.0000000000000481, doi:10.1097/wco.0000000000000481. This article has 83 citations and is from a peer-reviewed journal.
(alessandro2018differencesbetweenacute‐onset pages 1-8): Lucas Alessandro, José M. Pastor Rueda, Miguel Wilken, Luis Querol, Mariano Marrodán, Julián N. Acosta, Alberto Rivero, Fabio Barroso, and Mauricio F. Farez. Differences between acute‐onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. Journal of the Peripheral Nervous System, 23:154-158, Jun 2018. URL: https://doi.org/10.1111/jns.12266, doi:10.1111/jns.12266. This article has 49 citations and is from a peer-reviewed journal.
(doorn2024challengesinthe media a605ddf1): Iris van Doorn, Filip Eftimov, Luuk Wieske, Ivo van Schaik, and Camiel Verhamme. Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives. Therapeutics and Clinical Risk Management, 20:111-126, Feb 2024. URL: https://doi.org/10.2147/tcrm.s360249, doi:10.2147/tcrm.s360249. This article has 17 citations and is from a peer-reviewed journal.
(oh2003subacuteinflammatorydemyelinating pages 2-3): S. J. Oh, K. Kurokawa, D. F. de Almeida, H. F. Ryan, and G. C. Claussen. Subacute inflammatory demyelinating polyneuropathy. Neurology, 61:1507-1512, Dec 2003. URL: https://doi.org/10.1212/01.wnl.0000096166.28131.4c, doi:10.1212/01.wnl.0000096166.28131.4c. This article has 137 citations and is from a highest quality peer-reviewed journal.
(stino2021chronicinflammatorydemyelinating pages 1-3): Amro M. Stino, Elie Naddaf, Peter J. Dyck, and P. James B. Dyck. Chronic inflammatory demyelinating polyradiculoneuropathy—diagnostic pitfalls and treatment approach. Muscle & Nerve, 63:157-169, Sep 2021. URL: https://doi.org/10.1002/mus.27046, doi:10.1002/mus.27046. This article has 91 citations and is from a peer-reviewed journal.
(ramchandren2009chronicneuropathieschronicinflammatory pages 3-6): S Ramchandren and RA Lewis. Chronic neuropathies-chronic inflammatory demyelinating neuropathy and its variants. Unknown journal, 2009.
(doorn2024challengesinthe pages 1-2): Iris van Doorn, Filip Eftimov, Luuk Wieske, Ivo van Schaik, and Camiel Verhamme. Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives. Therapeutics and Clinical Risk Management, 20:111-126, Feb 2024. URL: https://doi.org/10.2147/tcrm.s360249, doi:10.2147/tcrm.s360249. This article has 17 citations and is from a peer-reviewed journal.
(doorn2024challengesinthe pages 2-3): Iris van Doorn, Filip Eftimov, Luuk Wieske, Ivo van Schaik, and Camiel Verhamme. Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives. Therapeutics and Clinical Risk Management, 20:111-126, Feb 2024. URL: https://doi.org/10.2147/tcrm.s360249, doi:10.2147/tcrm.s360249. This article has 17 citations and is from a peer-reviewed journal.
(kmezic2023validationofelevated pages 1-2): Ivan Kmezic, Rasmus Gustafsson, Katharina Fink, Anders Svenningsson, Kristin Samuelsson, Caroline Ingre, Tomas Olsson, Magnus Hansson, Ingrid Kockum, Milena Z. Adzemovic, and Rayomand Press. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with gbs and cidp using a proximity extension assay. Frontiers in Immunology, Nov 2023. URL: https://doi.org/10.3389/fimmu.2023.1241199, doi:10.3389/fimmu.2023.1241199. This article has 11 citations and is from a peer-reviewed journal.
(kmezic2023validationofelevated pages 3-4): Ivan Kmezic, Rasmus Gustafsson, Katharina Fink, Anders Svenningsson, Kristin Samuelsson, Caroline Ingre, Tomas Olsson, Magnus Hansson, Ingrid Kockum, Milena Z. Adzemovic, and Rayomand Press. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with gbs and cidp using a proximity extension assay. Frontiers in Immunology, Nov 2023. URL: https://doi.org/10.3389/fimmu.2023.1241199, doi:10.3389/fimmu.2023.1241199. This article has 11 citations and is from a peer-reviewed journal.
(ramchandren2009chronicneuropathieschronicinflammatory pages 1-3): S Ramchandren and RA Lewis. Chronic neuropathies-chronic inflammatory demyelinating neuropathy and its variants. Unknown journal, 2009.
(kmezic2025biomarkerandpathogenic pages 29-35): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.
(dyck2018historydiagnosisand pages 2-3): P. James B. Dyck and Jennifer A. Tracy. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clinic Proceedings, 93:777–793, Jun 2018. URL: https://doi.org/10.1016/j.mayocp.2018.03.026, doi:10.1016/j.mayocp.2018.03.026. This article has 161 citations and is from a domain leading peer-reviewed journal.
(bunschoten2019progressindiagnosis pages 3-5): Carina Bunschoten, Bart C Jacobs, Peter Y K Van den Bergh, David R Cornblath, and Pieter A van Doorn. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. The Lancet Neurology, 18:784-794, Aug 2019. URL: https://doi.org/10.1016/s1474-4422(19)30144-9, doi:10.1016/s1474-4422(19)30144-9. This article has 288 citations and is from a highest quality peer-reviewed journal.
(mathey2015chronicinflammatorydemyelinating pages 3-4): Emily K Mathey, Susanna B Park, Richard A C Hughes, John D Pollard, Patricia J Armati, Michael H Barnett, Bruce V Taylor, P James B Dyck, Matthew C Kiernan, and Cindy S-Y Lin. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Journal of Neurology, Neurosurgery & Psychiatry, 86:973-985, Feb 2015. URL: https://doi.org/10.1136/jnnp-2014-309697, doi:10.1136/jnnp-2014-309697. This article has 561 citations.
(doorn2024challengesinthe media 1489a645): Iris van Doorn, Filip Eftimov, Luuk Wieske, Ivo van Schaik, and Camiel Verhamme. Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives. Therapeutics and Clinical Risk Management, 20:111-126, Feb 2024. URL: https://doi.org/10.2147/tcrm.s360249, doi:10.2147/tcrm.s360249. This article has 17 citations and is from a peer-reviewed journal.
(doorn2024challengesinthe media be7d2bb3): Iris van Doorn, Filip Eftimov, Luuk Wieske, Ivo van Schaik, and Camiel Verhamme. Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives. Therapeutics and Clinical Risk Management, 20:111-126, Feb 2024. URL: https://doi.org/10.2147/tcrm.s360249, doi:10.2147/tcrm.s360249. This article has 17 citations and is from a peer-reviewed journal.
(doorn2024challengesinthe media b86e8bf0): Iris van Doorn, Filip Eftimov, Luuk Wieske, Ivo van Schaik, and Camiel Verhamme. Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives. Therapeutics and Clinical Risk Management, 20:111-126, Feb 2024. URL: https://doi.org/10.2147/tcrm.s360249, doi:10.2147/tcrm.s360249. This article has 17 citations and is from a peer-reviewed journal.
(doorn2024challengesinthe media 87bdfab1): Iris van Doorn, Filip Eftimov, Luuk Wieske, Ivo van Schaik, and Camiel Verhamme. Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives. Therapeutics and Clinical Risk Management, 20:111-126, Feb 2024. URL: https://doi.org/10.2147/tcrm.s360249, doi:10.2147/tcrm.s360249. This article has 17 citations and is from a peer-reviewed journal.
(kmezic2023validationofelevated pages 2-3): Ivan Kmezic, Rasmus Gustafsson, Katharina Fink, Anders Svenningsson, Kristin Samuelsson, Caroline Ingre, Tomas Olsson, Magnus Hansson, Ingrid Kockum, Milena Z. Adzemovic, and Rayomand Press. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with gbs and cidp using a proximity extension assay. Frontiers in Immunology, Nov 2023. URL: https://doi.org/10.3389/fimmu.2023.1241199, doi:10.3389/fimmu.2023.1241199. This article has 11 citations and is from a peer-reviewed journal.
(kmezic2025biomarkerandpathogenic pages 41-44): Ivan Kmezic. Biomarker and pathogenic study of immune-mediated neuropathies. Apr 2025. URL: https://doi.org/10.69622/28457924.v1, doi:10.69622/28457924.v1.